SCA Pharmaceuticals LLC

SCA Pharmaceuticals, also known by its alias, is a company headquartered in the United States of America. The organization’s name indicates its involvement in the pharmaceutical industry. As a pharmaceutical entity, it is engaged in activities such as the research, development, production, and distribution of medicinal products. This sector positioning places it within a regulated market focused on healthcare solutions.

On July 5, 2022, SCA Pharmaceuticals experienced a malware attack that enabled unauthorized access to its internal network. The intrusion resulted in the exposure of a range of sensitive consumer data. Compromised information included names, dates of birth, Social Security numbers, government identifiers, health information, and bank account details. Upon detection, the company secured its systems and terminated the intrusion. An investigation was conducted to confirm the extent of the unauthorized data exposure before affected individuals were notified.

The types of data compromised reveal that SCA Pharmaceuticals maintains personal identifiers and financial information alongside health-related records. This suggests the organization processes consumer data as part of its business operations, possibly linked to patient services or prescription management. Handling such data subjects the company to various privacy and security regulations governing protected health information and financial data. The incident underscores the importance of robust cybersecurity measures for entities managing sensitive personal information.

Beyond the incident details and headquarters location, the provided sources do not disclose specific metrics regarding the company’s size, workforce, revenue, or market reach. Information about ownership structure, parent companies, or subsidiaries is also not available in the given material. Consequently, any description of SCA Pharmaceuticals’ scale or corporate affiliations remains unspecified based on the current information. The profile therefore focuses on the confirmed facts of its pharmaceutical sector involvement, U.S. headquarters, and the 2022 data security incident.